Status:
UNKNOWN
Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery
Lead Sponsor:
St. Elizabeth Cancer Institute, Slovakia
Collaborating Sponsors:
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Louis Pasteur University Hospital Kosice
Conditions:
Inflammatory Markers
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The study will test the hypothesis that inflammatory markers measured at 24 hours after breast cancer surgery will be lower in patients receiving PECS II and PIFB blocks, supplemented with dexmetomidi...
Detailed Description
Breast cancer is a devastating disease. Surgery is the mainstay of treatment which can lead to ongoing patient difficulties. Severe acute pain after surgery is one of major risk factors for developing...
Eligibility Criteria
Inclusion
- Female patients with ductal carcinoma (stage 1 to 3) undergoing primary potentially curative unilateral mastectomy.
- Older than 18 years
- ASA I-III
Exclusion
- Weight \< 50 kg
- BMI \> 35
- Allergy to local anaesthetic or dexmetomidine
- Contraindications to NSAIDs use
- Local infection over block site
- Coagulopathy
- Preexisting chronic pain
- Pregnancy
- Autoimmune disease
- Inability to give informed consent
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04860115
Start Date
November 1 2021
End Date
December 1 2023
Last Update
September 28 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.